Methods for treating hyperactive gastrointestinal motility
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/404
A61K-031/403
출원번호
US-0635081
(2003-08-06)
발명자
/ 주소
Argentieri,Thomas M.
출원인 / 주소
Wyeth
인용정보
피인용 횟수 :
0인용 특허 :
9
초록
This invention provides methods for the treatment or inhibition of hyperactive gastrointestinal motility in a mammal utilizing compounds having the formula: where R, and R1 to R6 are described herein.
대표청구항▼
What is claimed is: 1. A method of treatment or inhibition of hyperactive gastrointestinal motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of a compound of the formula: wherein: R is hydrogen, hydroxy or fluoro; R1, R2, R
What is claimed is: 1. A method of treatment or inhibition of hyperactive gastrointestinal motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of a compound of the formula: wherein: R is hydrogen, hydroxy or fluoro; R1, R2, R3 and R4 each are independently hydrogen, C1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R1 and R2, R2 and R3 or R3 and R4 are joined together to form a benzo-fused ring; R5 is hydrogen or C1-4 alkyl; and R6 is chlorine or trifluoromethyl; or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof. 2. The method of claim 1 wherein the compound is selected from at least one of: (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2-H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-7-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-trifluoromethyl)2H-indol-2-one; (짹)-1,3-Dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl) phenyl]-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis(trifluoromethyl)-2H-indol-2-one; (-)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one; (-)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[g]indol-2one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[g]indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(4-methylphenyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoromethyl)-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e]indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-4,6-bis(trifluoromethyl)-2H-indol-2-one; (짹)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-2H-indol-2one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-[4-(trifluoromethyl)phenyl]-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one; (짹)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indol-2-one; (짹)-3-(5-Chloro-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indol-2-one; (짹)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one; (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one; or (짹)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one; or a pharmaceutically acceptable salt form thereof. 3. The method of claim 1 wherein the mammal is a human. 4. The method of claim 1 wherein the mammal is feline or canine. 5. The method of claim 1 wherein the hyperactive gastrointestinal motility in a mammal is associated with irritable bowel syndrome. 6. The method of claim 1 wherein the hyperactive gastrointestinal motility in a mammal is associated with Crohn's disease. 7. The method of claim 1 wherein the hyperactive gastrointestinal motility in a mammal is associated with diarrhea. 8. The method of claim 1 wherein the hyperactive gastrointestinal motility in a mammal is associated with colitis. 9. The method of claim 1 wherein the hyperactive gastrointestinal motility in a mammal is associated with postprandial urgency or postprandial accentuation of diarrhea.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (9)
Hewawasam Piyasena (Middletown CT) Meanwell Nicholas A. (East Hampton CT) Gribkoff Valentin K. (Wallingford CT), 3-substituted oxindole derivatives as potassium channel modulators.
Dieter Hans-Reinhold (Darmstadt DEX) Engel Jurgen (Alzenau DEX) Kutscher Bernhard (Maintal DEX) Polymeropoulos Emanuel (Frankfurt DEX) Szelenyi Stefan (Schwaig DEX) Nickel Bernd (Muhltal DEX), Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositi.
Rostock Angelika,DEX ; Rundfeldt Chris,DEX ; Tober Christine,DEX ; Bartsch Reni,DEX, Use of 2-4-amino-4-(4-fluorobenzylamino) (-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the neurod.
Rostock Angelika,DEX ; Rundfeldt Chris,DEX ; Tober Christine,DEX ; Bartsch Reni,DEX, Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of reduced cerebr.
Rundfeldt Chris,DEX ; Bartsch Reni,DEX ; Rostock Angelika,DEX ; Tober Christine,DEX ; Dost Rita,DEX, Use of retigabine for the treatment of neuropathic pain.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.